血必净注射液改善急性胰腺炎肺通气疗效的系统评价与Meta分析
该研究通过系统检索8个数据库至2024年9月,纳入相关文献进行Meta分析,评估血必净注射液联合常规治疗对急性胰腺炎患者肺功能的影响。结论提示联合血必净可能提高氧合指数、降低呼吸频率、改善APACHE II评分及炎症生物标志物,但纳入研究偏倚风险高、质量低,需更多多中心大样本高质量试验验证。
要点
- 血必净联合常规治疗可能提高急性胰腺炎患者氧合指数。
- 联合治疗可能降低呼吸频率并改善APACHE II评分。
- 证据质量低、偏倚风险高,结论需谨慎解读。
核心结论
- 常规治疗联合血必净注射液可能改善急性胰腺炎患者氧合指数、呼吸频率、APACHE II评分及炎症生物标志物。
- 但纳入研究偏倚风险高、质量低,需更多多中心大样本高质量试验验证。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Cochrane Library等8个数据库至2024年9月。
- 由两名研究者独立筛选文献、提取数据,采用Cochrane风险偏倚2.0工具评估质量,使用Review Manager软件分析。
主要发现
- 血必净联合常规治疗可能提高氧合指数。
- 血必净联合常规治疗可能降低呼吸频率。
- 血必净联合常规治疗可能改善APACHE II评分和炎症生物标志物。
临床怎么用
- 在常规治疗基础上,可考虑联合血必净注射液以改善急性胰腺炎患者的肺通气相关指标。
- 临床应用时应充分告知证据质量低、偏倚风险高,需结合患者具体情况个体化决策。
局限性
- 纳入研究偏倚风险高,整体证据质量低。
- 需更多设计良好、大样本、多中心的高质量试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xuebijing injection (XBJI), as a Chinese patent medicine injection, consists of five botanical drugs for anti-inflammatory treatment. Acute pancreatitis (AP) is induced by localized inflammation, potentially resulting in multiple organ dysfunction syndromes, specifically including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Recent studies suggest that XBJI effective in alleviating potentially easing ALI and ARDS. OBJECTIVE: We illustrated the efficacy and safety of XBJI for pulmonary function of AP by conducting a systematic literature review and meta-analysis. METHODS: We conducted searches across eight databases, including PubMed, Embase, and the Cochrane Library, up to September 2024. Two independent investigators screened and selected the literature based on predefined inclusion and exclusion criteria, followed by data extraction. The quality of the selected studies was assessed using the Cochrane Collaboration's Risk of Bias 2.0 tool. The data were then qualitatively analyzed and synthesized by using Review Manager software, in accordance with the PRISMA guidelines and the Cochrane Handbook. CONCLUSION: This study showed that using conventional therapy combined with XBJI might increase the oxygenation index, lower the respiratory rate, and improve APACHE II scores and inflammatory biomarkers. However, there is a high risk of bias and the quality of the included studies is low. More well-designed, large-sample, and high-quality trials are needed to be conducted in multiple centers.
引用
- Bin Y, Peng R, Lee Y, et al. Efficacy of Xuebijing injection on pulmonary ventilation improvement in acute pancreatitis: a systematic review and meta-analysis. Front Pharmacol. 2025. PMID: 40308770. doi:10.3389/fphar.2025.1549419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。